Hansen Clinic

Call Today! (480) 991-5092.

Schedule an Appointment

Good News for your Bioidentical Hormones

by | Dec 4, 2014

Print Friendly, PDF & Email


On October 20th, 2014, I told you about new legislation that has placed onerous new restrictions on Compounding Pharmacies.

  1. Compounding Pharmacies can no longer sell Bio-Identical Hormones in bulk to doctors office’s.
  2. Each formulation must be prescribed individually for a specific patient
  3. Each compounded medication must be made individually by hand for each patient
  4. Supplies of Compounded Medications are limited by the FDA to 5% of their total prescriptions out of state
  5. Massive increases in time and paperwork must be employed to prepare and track each new prescription
  6. Additional administrative and legal fees will be required to meet these oppressively burdensome new regulations

The bottom line is that “Big Pharma†is taking advantage of an isolated tragedy to squeeze “little compounding pharmacies†and the doctors that use their products out of business. As a Naturopathic Physician and a Diplomat of the World Society of Anti-Aging Medicine, I am one of the few Physicians who who is medically trained in and prefers to prescribe Natural Medicines and Bioidentical Hormones rather than synthetic, patented drugs. Why, because they work and they are better for my patients. When Congress and Big Phama say they know better, what they are really saying is, they want more money. We are fighting to retain your freedom of choice in health care and your right to choose Natural Medicines and Bioideintical Hormones.

Good News!

We have good news! Unfortunately, we will no longer be able to order Bioidentical Hormones in bulk to have on hand at out office and dispense in unlimited variations as we were able to do before the change in the law. However, we have been able to formulate 12 Hansen Clinic exclusive Bioidentical Hormone combinations, which will allow 95% of all our patients to consolidate their dosing from 3 Capsules per night to 1 Capsule. Hooray for fewer pills! I expect that this change will provide the same positive benefits and make taking your hormones faster and easier.

Call to Action

We will need to ask you for your kind cooperation as we make this transition. We would ask that you please call at least two weeks ahead of time to order your next prescription. Please bare with us as we will only be able to give you a 30 day supply for the first new order. Subsequent orders will be for 60 days when refilled. Please make your scheduled appointments for your Hormone Testing 3-4 weeks before you run out of hormones, so that we can make any necessary changes to your prescription before ordering your new combination.
We greatly appreciate your understanding and cooperation as well as your letters written to your Congressman in support of your right to choose Natural Alternatives and Bioidentical Hormones. We will continue to fight the good fight for your freedom to choose Natural Alternatives and Preventive Medicines.
 
Sincerely,
A green chalkboard with the message 'I LOVE YOU' written in white chalk.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Click Here to see the full Report of the Research
Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Join Our Community

Call to Schedule Your Appointment Today! (480) 991-5092.

Receive Our Newsletter

10 + 14 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });